Full Press Release Details
MALVERN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and third quarter 2025 financial results.
"The past quarter delivered breakthrough progress on every front," said Maria Maccecchini, Ph.D., President and CEO of Annovis. "Our pivotal Phase 3 Alzheimer's study has achieved full activation across all clinical sites, with enrollment momentum advancing every day. We have fortified our intellectual property position by transferring all patents to our new crystal form of buntanetap while publishing compelling pharmacokinetic data that validates this milestone. The addition of a seasoned CFO strengthens our executive team precisely when it matters most. Adding to all this, we are particularly encouraged by the new biomarker findings from our Phase 2/3 study showing meaningful reductions in inflammation and neurodegeneration—powerful evidence of buntanetap's disease-modifying potential. Every element is now aligned as we move toward our data readouts—the final step before an NDA submission."
Clinical highlights – pivotal Phase 3 AD study
Business highlights
Financial results
About AnnovisHeadquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as AD and PD. The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visitwww.annovisbio.comand follow us onLinkedIn,YouTube, andX.
Investor AlertsInterested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts athttps://www.annovisbio.com/email-alerts.
Forward-Looking StatementsThis press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.
Contact Information:Annovis Bio Inc.101 Lindenwood DriveSuite 225Malvern, PA 19355www.annovisbio.com
Investor Contact:Alexander Morin, Ph.D.Director, Strategic CommunicationsAnnovis Bioir@annovisbio.com
(Tables to follow)
| Annovis Bio, Inc. | ||||||||
| Balance Sheets | ||||||||
| September 30, | ||||||||
| 2025 | December 31, | |||||||
| (Unaudited) | 2024 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 15,286,399 | $ | 10,551,916 | ||||
| Prepaid expenses and other current assets | 1,902,562 | 3,373,717 | ||||||
| Total assets | $ | 17,188,961 | $ | 13,925,633 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 2,112,026 | $ | 2,305,974 | ||||
| Accrued expenses | 1,621,771 | 1,575,013 | ||||||
| Total current liabilities | 3,733,797 | 3,880,987 | ||||||
| Non-current liabilities: | ||||||||
| Warrant liability | 299,000 | 737,000 | ||||||
| Total liabilities | 4,032,797 | 4,617,987 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity: | ||||||||
| Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding | — | — | ||||||
| Common stock | 2,019 | 1,414 | ||||||
| Additional paid-in capital | 167,023,392 | 144,155,694 | ||||||
| Accumulated deficit | (153,869,247 | ) | (134,849,462 | ) | ||||
| Total stockholders’ equity | 13,156,164 | 9,307,646 | ||||||
| Total liabilities and stockholders’ equity | $ | 17,188,961 | $ | 13,925,633 |
| Annovis Bio, Inc. | ||||||||||||||||
| Statement of Operations | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | $ | 6,291,171 | $ | 2,689,561 | $ | 16,464,609 | $ | 14,996,868 | ||||||||
| General and administrative | 1,143,804 | 1,698,050 | 3,524,500 | 4,963,188 | ||||||||||||
| Total operating expenses | 7,434,975 | 4,387,611 | 19,989,109 | 19,960,056 | ||||||||||||
| Operating loss | (7,434,975 | ) | (4,387,611 | ) | (19,989,109 | ) | (19,960,056 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest income | 152,317 | 135,430 | 531,324 | 205,576 | ||||||||||||
| Other financing costs | — | (524,068 | ) | — | (1,870,128 | ) | ||||||||||
| Change in fair value of warrants | 20,000 | (7,862,108 | ) | 438,000 | 2,898,892 | |||||||||||
| Total other income, net | 172,317 | (8,250,746 | ) | 969,324 | 1,234,340 | |||||||||||
| Net loss | $ | (7,262,658 | ) | $ | (12,638,357 | ) | $ | (19,019,785 | ) | $ | (18,725,716 | ) | ||||
| Net loss per share | ||||||||||||||||
| Basic | $ | (0.37 | ) | $ | (0.97 | ) | $ | (1.01 | ) | $ | (1.64 | ) | ||||
| Diluted | $ | (0.37 | ) | $ | (0.97 | ) | $ | (1.01 | ) | $ | (1.89 | ) | ||||
| Weighted-average number of common shares used in computing net loss per share | ||||||||||||||||
| Basic | 19,685,071 | 12,975,808 | 18,876,078 | 11,394,729 | ||||||||||||
| Diluted | 19,685,071 | 12,975,808 | 18,876,078 | 11,461,298 |